Case Study 3
Skimune®Pharm is designed to predict first-in-man hypersensitivity or adverse immune reactions in response to small or large molecule therapeutics.
Our client, a global pharmaceutical company requested Alcyomics to determine human in vitro responses to a number of small molecule drugs known to be associated or not associated with adverse immune reactions. The study, involving the use of Skimune®Pharm, was performed blinded to outcome. Results showed a positive response to phenobarbital (grade III response) and a negative response to metformin and sulphamethoxazole (see Figure1). A 0.86 correlation coefficient between Skimune®Pharm results and clinical outcome was determined. The high correlation to clinical outcome indicates the strong predictive capacity of the Skimune®Pharm assay and how it can be used as a pre-clinical tool to determine immunotoxicity of therapeutic drugs.
Figure 1 Histopathological analysis of the adverse effects of small molecule drugs. Skin incubated with phenobarbital showing a grade III positive response, metformin and sulphamethoxazole showing a grade I negative response (B,C respectively). In the positive biopsy (A) arrows point to vacuolisation of keratinocytes and cleft formation.